Hospital management after acute coronary syndromes: Is the risk over ?
EAS Academy, Jose L. Zamorano, 217700
Molecular and biochemical mechanisms involved in the protective effect of Mediterranean diet against atherosclerosis
EAS Academy, Alvaro Hernaez, 217696
Effects of the different dietary fatty acids on health: focus on PUFA n-6. New evidences and controversies
EAS Academy, Andrea Poli, 217695
Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil
EAS Academy, Emilio Ros, 217694
Diet and CVD the epidemiological view
EAS Academy, Salim Yusuf, 217693
The multifaceted aspects of CV prevention: from nutrition to therapy: Chair
EAS Academy, Prof. Alberico L. Catapano, Dr. Alberto Mello e Silva & Dr. Xavier Pinto, 218363
Systemsbiology and cardiovascular disease
EAS Academy, Jörg Menche, 202892
Gut microbiome and atherothrombosis
EAS Academy, Christoph Reinhardt, 202891
EAS Academy, Steffen Massberg, 202888
Monocytes and atherothrombosis
EAS Academy, Johann Wojta, 202889
Clotting factors and atherothrombosis
EAS Academy, Hugo ten Cate, 202886
Humoral immunity and thrombosis
EAS Academy, Christoph Binder, 202890
Antiphospholipid antibodies and thrombosis
EAS Academy, Karl Lackner, 202885
Venous vs. arterial thrombosis
EAS Academy, Cihan Ay, 202881
Tissue Factor
EAS Academy, Nigel Mackman, 202883
Platelets and the vascular wall
EAS Academy, R Koenen, 202882
Mechanisms of plaque rupture and erosion
EAS Academy, Gerard Pasterkamp, 202879
Clinical aspects of atherothrombosis
EAS Academy, Irene Lang, 202878
Plasma lipoproteins and atherogenesis: The central role of apo B containing lipoproteins
EAS Academy, Jan Borén, 205838
HDL, non-HDL cholesterol and TG, a role in atherosclerosis?
EAS Academy, Jan Borén, 205839
Lipid lowering strategies - highlights from recent publications
EAS Academy, Alberico Luigi Catapano, 205840
Lipid guidelines; where do we stand?
EAS Academy, Alberico Luigi Catapano, 205841
CVD: Epidemiology of the risk factors - the central role of LDL cholesterol
EAS Academy, Lale Tokgozoglu, 205842
PCSK9: From promise to clinical practice and an analysis of recent trials
EAS Academy, Alberico Luigi Catapano, 205843
Will precision medicine help tailor dyslipidemia treatment?
EAS Academy, Alberto Zambon, 200946
Can we refine strategy on HDL by new pharmacological approaches?
EAS Academy, John Chapman, 200945
Identification of novel targets in Hypertension and priorities for drug development
EAS Academy, David Rosenbaum, 200944
Nutrigenomics for prevention and treatment of obesity
EAS Academy, Judith Aron-Wisnewsky, 200942
Is there a role for Advanced Atherosclerosis Imaging in targeted cardiovascular therapy?
EAS Academy, Erik Stroes, 200941
Do Novel Biomarkers improve cardiovascular risk stratification?
EAS Academy, Arnold von Eckardstein, 200940
Human Genetics from validation of novel cardiovascular drug targets to molecular diagnosis
EAS Academy, Alain Carrié, 200939
Precision Cardiovascular Medicine: an unmet need or just a fashion?
EAS Academy, Eran Leitersdorf, 200938
News from ESC: the REVEAL trial
EAS Academy, Alberico Luigi Catapano, 193805
News from ESC: the CANTOS trial
EAS Academy, Alberico Luigi Catapano, 196302
News from ESC: an update from the FOURIER study
EAS Academy, Alberico Luigi Catapano, 196303
An introduction to Familial Hypercholesterolaemia for clinicians
EAS Academy, Stefano Romeo, 183923
Treatment of FH: Diet, statin and statin intolerance
EAS Academy, Olov Wiklund, 183924
FH in children
EAS Academy, Albert Wiegman, 183925
Proprotein convertase subtilisin/kexin type 9 inhibitors
EAS Academy, Ulf Landmesser, 183926
Brown adipose tissue: a novel target to comBAT cardiometabolic disease
EAS Academy, Patrick Rensen, 175540
Circadian control of metabolism
EAS Academy, Frank A.J.L. Scheer, 175539
Importance of physical activity in metabolic and cardiovascular health and the influence of obesity and diabetes
EAS Academy, Patrick Schrauwen, 175538
Microbiome and cardiometabolic disease
EAS Academy, Fredrik Bäckhed, 175537
Diet and cardiometabolic health
EAS Academy, Qi Sun, 175536
Large-scale epidemiology assessment of the main determinants of cardiovascular disease
EAS Academy, Sarah Lewington, 175535
Mechanistic insights into innovative therapeutics in lipid lowering in vivo
EAS Academy, Henry Ginsberg, 175534
Temporal versus one-time biomarker measurements
EAS Academy, Lind Lars, 175530
Circulating miRNA for cardiovascular death prediction
EAS Academy, Tanja Zeller, 175529
Typical clinical cases: who may benefit?
EAS Academy, Eric Bruckert, 175527
The clinical evidence: Meta-analysis of the RCT
EAS Academy, Matteo Pirro, 175526
Updates on the guidelines. Which role for nutraceuticals?
EAS Academy, Emilio Ros, 175525
EAS Academy, Marc Dweck, 175524
CT angiography
EAS Academy, Jason M. Tarkin, 175523
3D ultrasound
EAS Academy, Stephen Nicholls, 175522
Introduction to Detecting plaque burden or vulnerable plaque: Which way should we go?
EAS Academy, Lale Tokgozoglu, 176682
EAS Academy, Course Faculty, 258495
Demystifying the management of hypertriglyceridemia
EAS Academy, Anne Tybjaerg-Hansen, 175521
Hepatic lipid and lipoprotein metabolism
EAS Academy, Marja-Riitta Taskinen, 175520
Regulation of lipid mobilization and lipoprotein secretion by the intestine
EAS Academy, Gary Lewis, 175519
How to treat diabetic dyslipidaemia: Introduction
EAS Academy, Borge Nordestgaard, 175531
How to treat diabetic dyslipidaemia
EAS Academy, Gerald Watts, 175532
How to treat diabetic dyslipidaemia
EAS Academy, Alberto Zambon, 175533
Balancing the fat: lipid droplets and human disease
EAS Academy, Robert Farese, Jr, 175518
EAS Academy, Course Faculty, 258494
How LDL causes inflammation in the artery wall
EAS Academy, Goran Hansson, 175517
HDL-cholesterol and cardiovascular disease: rethinking our approach
EAS Academy, John Chapman, 175516
Hypertriglyceridaemia: ApoC-III and ANGPTL3
EAS Academy, Sotirios Tsimikas, 175515
CVD prevention strategies: Discussion
EAS Academy, Session Speakers, 176681
Combination therapy a better way to treat?
EAS Academy, Lale Tokgozoglu, 175514
The value of generic medicines
EAS Academy, Gianni Corrao, 175513
DISCUSSION: What do FOURIER data mean for clinical practice?
EAS Academy, Session Speakers, 175508
Atherosclerosis regression: linking GLAGOV and FOURIER
EAS Academy, Stephen Nicholls, 175507
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Discussion
EAS Academy, Session Speakers, 176676
LAL deficiency: Discussion
EAS Academy, Session Speakers, 176678
EAS Academy, Course Faculty, 258493
Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency
EAS Academy, Reena Sharma, 175510
Fibrates in the management of AD and CVD risk
EAS Academy, Michal Vrablik, 175512
FOURIER: first outcomes data with a PCSK9 inhibitor
EAS Academy, Terje R Pedersen, 175506
Atherogenic dyslipidemia (AD)
EAS Academy, Alberto Zambon, 175511
EAS Academy, Course Faculty, 258492
LDL is causal to atherosclerosis
EAS Academy, John Chapman, 175505
Lysosomal acid lipase deficiency - an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction
EAS Academy, Maurizio Averna, 175509
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Introduction
EAS Academy, Kausik Ray, 176674
Chronic kidney disease
EAS Academy, Alexandros Tselepis, 175502
Familial hypercholesterolaemia
EAS Academy, Kausik Ray, 175500
Primary prevention
EAS Academy, Guy de Backer, 175499
Secondary prevention
EAS Academy, Renata Cifkova, 175498
Prognostics in patients with manifest (acute or chronic) CHD
EAS Academy, Thomas Luscher, 175504
EAS Academy, Course Faculty, 258491
Summary and introduction of guidelines
EAS Academy, Alberico Luigi Catapano, 175497
Using naturally randomized genetic evidence to understand heritability of coronary artery disease?
EAS Academy, Brian Ference, 175503
Lowering LDL-C for cardiovascular disease
EAS Academy, Chris Packard, 175496
The case for immune cells: An expanded cardiovascular continuum
EAS Academy, Peter Libby, 175495
Innate immune response drives atherosclerosis
EAS Academy, Mihai Netea, 175494
Role of non-coding RNA for cholesterol homeostasis and atherogenesis
EAS Academy, Kathryn Moore, 175493
Anitschkow Lecture: Hematopoiesis, cholesterol and atherosclerosis
EAS Academy, Alan Tall, 175492
Introduction to Anitschkow prize winner
EAS Academy, Lale Tokgozoglu, 176670

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings